Literature DB >> 3595072

S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.

S A Ward, F Goto, K Nakamura, E Jacqz, G R Wilkinson, R A Branch.   

Abstract

The 4-hydroxylation of S-mephenytoin exhibits polymorphism in both whites and Japanese such that the populations can be divided into extensive and poor metabolizers. To determine whether genetic constitution is a primary determinant in the expression of such metabolism, four extended Japanese families containing 13 sets of parent/offspring relationships were phenotyped for their mephenytoin 4-hydroxylation activity using the 8-hour urinary ratio of unchanged R- and S-mephenytoin as the trait measurement. The incidence of the poor metabolizer phenotype in these families was 2.2 times greater than that in an unrelated Japanese population. In three families in which both parents were poor metabolizers of mephenytoin, all six children also exhibited the poor metabolizer trait. The phenotype distribution for each family studied was consistent with the hypothesis that mephenytoin 4-hydroxylation activity is under diallelic, monogenic control, with the poor metabolizer phenotype being the autosomal recessive homozygous genotype and the extensive metabolizer phenotype including both the autosomal dominant and heterozygous genotypes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595072     DOI: 10.1038/clpt.1987.114

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.

Authors:  Yumiko Ohkubo; Akihito Ueta; Naoki Ando; Tetsuya Ito; Sachiko Yamaguchi; Kantaro Mizuno; Satoshi Sumi; Tohru Maeda; Daiju Yamazaki; Yukihisa Kurono; Shinji Fujimoto; Hajime Togari
Journal:  J Hum Genet       Date:  2005-11-24       Impact factor: 3.172

3.  The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

Authors:  H J Feng; S L Huang; W Wang; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 4.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

5.  Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Authors:  H G Xie; R B Kim; C M Stein; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

6.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

7.  The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

Authors:  S A Ward; N A Helsby; E Skjelbo; K Brøsen; L F Gram; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.